# Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

> **NCT00065182** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 399 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell
- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Topotecan/Docetaxel combination
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00065182
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08-14
- **Primary completion:** 2007-08-30
- **Final completion:** 2007-08-30
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2019-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065182, "Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00065182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*